3+ hour, 12+ min ago  (294+ words) Olubukola Ayodele, Breast Cancer Lead at University Hospitals of Leicester NHS Trust, shared a post on'Linked In: "One of the hardest realities in metastatic triple negative breast cancer is that some patients never receive a second line of therapy.'The…...

21+ hour, 18+ min ago  (66+ words) Mohammed Faisal Eltagalawi: Key Health System Requirements for Breast Cancer Control Oncodaily Mohammed Faisal Eltagalawi, Development Researcher at Qatar Cancer Society, shared a post on Linked In: "The Global Breast Cancer Initiative GBCI " WHO Outlines the health-system requirements needed to…...

1+ day, 4+ hour ago  (1245+ words) Breast oncology this week brought a clear message: progress is increasingly about precision, not simply escalation. From immune biomarkers that may reshape chemotherapy decisions in ER+/HER2" disease to the evolving role of ADCs, genomic testing, treatment de-escalation, and global quality…...

1+ week, 1+ day ago  (79+ words) Oncodaily Hosting Michelle Guevara-Nieto as a Postdoctoral Scientist to Investigate Breast Cancer Etiology " IARC International Agency for Research on Cancer shared a post on Linked In: "IARC, through support from The Mark Foundation for Cancer Research, is hosting Dr Hedda…...

1+ week, 3+ day ago  (324+ words) Sally Wolf, CEO and Founder of Light Works, shared a post on'Linked In: "I began using the term thriver when my cancer spread, but on days like today, when a cherished metastatic sister passes away, it feels so terribly off....

1+ week, 4+ day ago  (119+ words) Dominika Kormanov" Addresses European Parliament on Breast Cancer Policy Gaps - EUROPA DONNA Oncodaily EUROPA DONNA " The European Breast Cancer Coalition shared a post by Dominika Kormanov", Board Member at EUROPA DONNA " The European Breast Cancer Coalition, on Linked In, adding:…...

1+ week, 4+ day ago  (364+ words) My take from last week's breast cancer publications " June 8"14, 2026 1. Long-term Outcomes in Invasive Lobular Carcinoma ESMO Open Key message: ILC is not a lower-grade ductal cancer " its late mortality pattern and poor neoadjuvant response demand histology-specific management. 2. PADMA: CDK4/6i vs Chemotherapy…...

2+ week, 1+ day ago  (223+ words) Morgan Fox, Graduate Student in Cancer Biology Ph D Program at University of Colorado Anschutz Medical Campus, shared a post on X: "I'm excited to share our article in press in Nature Communications! This project encompasses the bulk of my dissertation…...

2+ week, 4+ day ago  (102+ words) Dana-Farber's Breast Oncology Center shared a post on X: "Drs. Ada Waks and Sarah Sammons introduce a patient case of a 62yearold woman with HER2+/HR- breast cancer. They discuss how to select an optimal firstline regimen for her amid an expanding range…...

3+ week, 1+ day ago  (206+ words) Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, shared a post on Linked In: "ASCO26 | Metastatic Breast Cancer Oral Session " Key Takeaways The recurring question: when 1 L data are positive, does benefit carry downstream? Several PFS2 analyses said…...